Keywords:
Pub Date:
From
Month
January February March April May June July August September October November December
Year
2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
To
Month
January February March April May June July August September October November December
Year
2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Paper Alert—HORIZON Trial Data Published
Cut to the Chase: Therapies Go Directly to Central Nervous System
NIH Funds Four Clinical Trials in ADCS Renewal
Solanezumab Selected for Alzheimer’s A4 Prevention Trial
Alzforum’s Top 12 of 2012
Tau-Targeting Drug Davunetide Washes Out in Phase 3 Trials
Q&A With Merck’s Johan Luthman
Solanezumab Heads for New Phase 3 Trial
Drug Company Halts Development of γ-Secretase Inhibitor Avagacestat
Merck Launches Largest Trial of BACE Inhibitor in AD
Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
The Solanezumab Benefit: Oh, So Small, But Probably Real
Bapineuzumab Phase 3: Target Engagement, But No Benefit
Paper Alert—GuidAge Trial Data on Ginkgo Biloba Published
Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?
Anticonvulsants Reverse AD-like Symptoms in Transgenic Mice
Clinical Trials of Intravenous Bapineuzumab Halted
Q&A With Roche’s CNS Leader Luca Santarelli
Luca Santarelli , who has moved into drug discovery research at Roche/Genentech and now oversees the AD therapy development program, among others...
No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
Novel Drug Knocks Aβ Off Synapses, Reduces Toxicity
Therapy Reported to Boost Cognition in Phase 2 Clinical Trial
Epilepsy Drug Calms the Hippocampus, Aids Memory
Keystone: Therapies Around ApoE—Has Their Time Come?
Bapineuzumab Crops CSF Tau Levels
Home
See our latest Webinar: 
